Clinical states model for biomarkers in bladder cancer

Future Oncology

Volumn 5, Issue 7, 2009, Pages 977-992

  Apolo, Andrea B ^a,b   Milowsky, Matthew ^a,b   Bajorin, Dean F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biomarkers; Bladder cancer; Chemotherapy; Clinical management

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CETUXIMAB; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MICRORNA; MICROSATELLITE DNA; NUCLEAR MATRIX PROTEIN 22; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; SURVIVIN; TELOMERASE; TUMOR ANTIGEN; UVOMORULIN; TUMOR MARKER;

ADVANCED CANCER; ASSAY; BLADDER CANCER; CANCER DIAGNOSIS; CANCER MODEL; CANCER PATIENT; CANCER RECURRENCE; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMAN; ONCOGENE H RAS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; UNITED STATES; UROGENITAL TRACT CANCER; BLADDER TUMOR; METABOLISM; RISK FACTOR;

HUMANS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 73349085595     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.57     Document Type: Review

References (136)

1. Whelan P: Bladder cancer - contemporary dilemmas in its management. Eur. Urol. 53(1), 24-26 (2008).
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18), 1315-1330 (2003).
3. Stein JP, Lieskovsky G, Cote R et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J. Clin. Oncol. 19(3), 666-675 (2001).
4. von der Maase H, Sengelov L, Roberts JT et al.: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23(21), 4602-4608 (2005).
5. Bishop J, Weinberg RA: Molecular Oncology. Scientific American, Inc., New York, NY, USA (1996).
6. Osman I, Bajorin DF, Sun T-T et al.: Novel blood biomarkers of human urinary bladder cancer. Clin. Cancer Res. 12(11), 3374-3380 (2006).
7. Apolo AB, Osman I, Shen R, Olshen AB, Bajorin DF: Peripheral-blood gene expression profiling in bladder cancer (BC) patients (pts). Proc. Am. Soc. Clin. Oncol. 26 (2008) (Abstract 5076).
8. Nagrath S, Sequist LV, Maheswaran S et al.: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173), 1235-1239 (2007).
9. Scher HI, Heller G: Clinical states in prostate cancer: towards a dynamic model of disease progression. Urology 55, 323-327 (2000).
10. Pagano F, Bassi P, Galetti TP et al.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J. Urol. 145(1), 45-50 (1991).
11. Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 7(361), 1927-1934 (2003).
12. Grossman HB, Natale RB, Tangen CM et al.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
13. Hall RR; on behalf of the Intl Collaboration of Trialists of the MRC Advanced Bladder Cancer Group MCTU, London, UK: Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc. Am. Soc. Clin. Oncol. 21, 178a (2002) (Abstract 710).
14. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48(2), 202-206 (2005).
15. Splinter TA, Scher HI, Denis L et al.: The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group. J. Urol. 147, 606-608 (1992).
16. Schultz PK, Herr HW, Zhang ZF et al.: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J. Clin. Oncol. 12(7), 1394-1401 (1994).
17. Herr HW: Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 54(1), 126-132 (2008).
18. von der Maase H, Hansen SW, Roberts JT et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized multicenter, multinational multicenter, Phase III study. J. Clin. Oncol. 18, 3068-3077 (2000).
19. Marrer E, Dieterle F: Biomarkers in oncology drug development: rescuers or troublemakers? Expert Opin. Drug Metab. Toxicol. 4(11), 1391-1402 (2008).
20. Messing EM, Madeb R, Young T et al.: Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107(9), 2173-2179 (2006). •• Landmark study that investigated the screening potential of hematuria for bladder cancer.
21. Hemstreet GP 3rd, Yin S, Ma Z et al.: Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J. Natl Cancer Inst. 93(6), 427-436 (2001).
22. Lotan Y, Svatek RS, Sagalowsky AI: Should we screen for bladder cancer in a high-risk population? Cancer 107(5), 982-990 (2006).
23. Black PC, Brown GA, Dinney CP: Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J. Clin. Oncol. 24(35), 5528-5535 (2006).
24. Lokeshwar VB, Habuchi T, Grossman HB et al.: Bladder tumor markers beyond cytology: International Consensus Panel on Bladder Tumor Markers. Urology 66(6 Suppl. 1), 35-63 (2005). •• One of the most comprehensive reviews of tumor markers in bladder cancer, summarizing the findings of the International Consensus Panel on cytology and bladder tumor markers.
25. Lokeshwar VB, Soloway MS: Current bladder tumor tests: does their projected utility fulfill clinical necessity? J. Urol. 165(4), 1067-1077 (2001).
26. Grossman HB, Soloway M, Messing E et al.: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3), 299-305 (2006). • Large prospective study investigating the detection of bladder cancer recurrence using a point-of-care assay for NMP-22.
27. Kumar A KR, Gupta NP: Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn. J. Clin. Oncol. 36(3), 172-175 (2006).
28. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J et al.: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol. 159(2), 394-398 (1998).
29. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M: Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J. Urol. 159(6), 1876-1880 (1998).
30. Sarosdy MF, Hudson MA, Ellis WJ et al.: Improved detection of recurrent bladder cancer using the bard BTA stat test. Urology 50(3), 349-353 (1997).
31. Heicappell R, Muller M, Fimmers R, Miller K: Qualitative determination of urinary human complement factor H-related protein (hcfHrp) in patients with bladder cancer, healthy controls, and patients with benign urologic disease. Urol. Int. 65(4), 181-184 (2000).
32. Pode D SA, Wald M, Nativ O, Laufer M, Kaver I: Noninvasive detection of bladder cancer with the BTA Stat test. J. Urol. 161(2), 443-446 (1999).
33. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL: Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumors. Urology 50(6), 882-887 (1997).
34. Thomas L, Leyh H, Marberger M et al.: Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin. Chem. 45(4), 472-477 (1999).
35. Alvarez A, Lokeshwar VB: Bladder cancer biomarkers: current developments and future implementation. Curr. Opin. Urol. 17(5), 341-346 (2007). • Discusses the development of novel biomarkers in bladder cancer over the last decade, and the lack of clinical implementation in the diagnosis and management of this disease.
36. Salz W, Eisenberg D, Plescia J et al.: A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 65(9), 3531-3534 (2005).
37. Altieri DC: Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3(1), 46-54 (2003).
38. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. JAMA 285(3), 324-328 (2001).
39. Weikert S CF, Schrader M, Krause H, Miller K, Müller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int. J. Cancer 116(1), 100-104 (2005).
40. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP: The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J. Cancer Res. Clin. Oncol. 134(6), 659-665 (2008).
41. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur. Urol. 52(5), 1388-1397 (2007).
42. Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O: A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J. Urol. 181(3), 1353-1360 (2009).
43. + in the detection and surveillance of urothelial carcinoma. Urology 61(1), 243-247 (2003).
44. Pfister C, Chautard D, Devonec M et al.: Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a french multicenter study. J. Urol. 169(3), 921-924 (2003).
45. Hautmann S, Toma M, Gomez MFL et al.: Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur. Urol. 46(4), 466-471 (2004).
46. Messing EM, Teot L, Korman H et al.: Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J. Urol. 174(4 Part 1), 1238-1241 (2005).
47. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M: Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 161(5), 1486-1489 (1999).
48. +/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 108(1), 60-65 (2006).
49. Lokeshwar VB, Iida N, Bourguignon LYW: The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J. Biol. Chem. 271(39), 23853-23864 (1996).
50. Eissa S, Kassim SK, Labib RA, El-Khouly IM et al.: Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 103(7), 1356-1362 (2005).
51. Yoder BJ, Skacel M, Hedgepeth R et al.: Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am. J. Clin. Pathol. 127(2), 295-301 (2007).
52. Sarosdy MF, Schellhammer P, Bokinsky G et al.: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 168(5), 1950-1954 (2002).
53. Friedrich MG, Toma AH, Pantel K, Weisenberger DJ, Noldus J, Huland H: Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int. 92(9), 911-914 (2003).
54. Laudadio J, Keane TE, Reeves HM et al.: Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 96(9), 1280-1285 (2005).
55. Zakian VA: Life and cancer without telomerase. Cell 91(1), 1-3 (1997).
56. Sanchini MA, Gunelli R, Nanni O et al.: Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294(16), 2052-2056 (2005).
57. Liu BCS, Loughlin KR: Telomerase in human bladder cancer. Urol. Clin. North Am. 27(1), 115-123 (2000).
58. Mao L, Schoenberg MP, Scicchitano M et al.: Molecular detection of primary bladder cancer by microsatellite ana lysis. Science 271(5249), 659-662 (1996).
59. Fearon ER, Feinberg AP, Hamilton SH, Vogelstein B: Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318(6044), 377-380 (1985).
60. Yoon DS, Li L, Zhang RD et al.: Genetic mapping and DNA sequence-based ana lysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease. Oncogene 20(36), 5005-5014 (2001).
61. Presti JC, Reuter VE, Galan T, Fair WR, Cordon-Cardo C: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 51, 5405-5409 (1991).
62. Frigerio S, Padberg BC, Strebel RT et al.: Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int. J. Cancer 121(2), 329-338 (2007).
63. Rouprêt M, Hupertan V, Yates DR et al.: A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int. 101(11), 1448-1453 (2008).
64. Knowles MA: Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol. 25(6), 581-593 (2007).
65. Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer 5(9), 713-725 (2005).
66. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24(33), 5218-5225 (2005).
67. Black PC, Agarwal PK, Dinney CP: Targeted therapies in bladder cancer - an update. Urol. Oncol. 25(5), 433-438 (2007).
68. Tomlinson DC, Baldo O, Harnden P, Knowles MA: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213(1), 91-98 (2007).
69. van Rhijn BW, Vis AN, van der Kwast TH et al.: Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21(10), 1912-1921 (2003).
70. Hernandez S, Lopez-Knowles E, Lloreta J et al.: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24(22), 3664-3671 (2006).
71. van Rhijn BWG, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 61(4), 1265-1268 (2001).
72. Lindgren D, Liedberg F, Andersson A et al.: Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25(18), 2685-2696 (2006).
73. Lopez-Knowles E, Hernandez S, Malats N et al.: PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 66(15), 7401-7404 (2006).
74. Hoque MO, Begum S, Brait M et al.: Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J. Urol. 179(2), 743-747 (2008).
75. Ellinger J, El Kassem N, Heukamp LC et al.: Hypermethylation of cell-free serum dna indicates worse outcome in patients with bladder cancer. J. Urol. 179(1), 346-352 (2008).
76. Vleminckx K, Vakaet L, Mareel M, Fiers W, Van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66(1), 107-119 (1991).
77. Durkan GC, Brotherick I, Mellon JK: The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin. BJU Int. 83(4), 424-428 (1999).
78. Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z: E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol. Int. 81(3), 320-324 (2008).
79. Pece S, Gutkind JS: Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J. Biol. Chem. 275(52), 41227-41233 (2000).
80. Black PC, Brown GA, Inamoto T et al.: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin. Cancer Res. 14(5), 1478-1486 (2008).
81. Edwards SL, Brough R, Lord CJ et al.: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182), 1111-1115 (2008).
82. Sakai W, Swisher EM, Karlan BY et al.: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451(7182), 1116-1120 (2008).
83. Bellmunt J, Albiol S, de Olano AR, Pujadas J, Maroto P; on behalf the Spanish Oncology Genitourinary Group: Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann. Oncol. 17(Suppl. 5), V113-V117 (2006).
84. Olaussen KA, Dunant A, Fouret P et al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006).
85. Ceppi P, Volante M, Novello S et al.: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 17(12), 1818-1825 (2006).
86. Bellmunt J, Paz-Ares L, Cuello M et al.: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 18(3), 522-528 (2007).
87. Kim K, Do I, Yi S et al.: ERCC1 expression in advanced bladder cancer patients receiving gemcitabine/cisplatin chemotherapy. Proc. Am. Soc. Clin. Oncol. (GU ASCO) (2009) (Abstract 269).
88. Taron M, Rosell R, Felip E et al.: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 13(20), 2443-2449 (2004).
89. Quinn JE, James CR, Stewart GE et al.: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res. 13(24), 7413-7420 (2007).
90. Font A, Taron M, Costa C et al.: BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy. Proc. Am. Soc. Clin. Oncol. 26(15 Suppl.), 5021 (2008).
91. Lee JK, Havaleshko DM, Cho H et al.: A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl Acad. Sci. USA 104(32), 13086-13091 (2007).
92. Sharma P, Shen Y, Wen S et al.: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl Acad. Sci. USA 104(10), 3967-3972 (2007).
93. Zhang L, Conejo-Garcia JR, Katsaros D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
94. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16), 3491-3494 (1998).
95. Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
96. +T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61(13), 5132-5136 (2001).
97. Danila DC, Heller G, Gignac GA et al.: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(23), 7053-7058 (2007).
98. Sastre J, Maestro ML, Puente J et al.: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann. Oncol. 19(5), 935-938 (2008).
99. Cristofanilli M, Budd GT, Ellis MJ et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
100. Gallagher DJ, Milowsky MI, Ishill N et al.: Detection of circulating tumor cells in patients with urothelial cancer. Ann. Oncol. 20(2), 305-308 (2009).
101. Wu C, Hao H, Li L et al.: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J. Thorac. Oncol. 4(1), 30-36 (2009).
102. de Bono JS, Scher HI, Montgomery RB et al.: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302-6309 (2008).
103. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA: The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med. 147(3), 126-132 (2006).
104. Malats N, Bustos A, Nascimento CM et al.: P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 6(9), 678-686 (2005).
105. Choi NN, Son DSD-S, Lee JJ et al.: The signature from messenger RNA expression profiling can predict lymph node metastasis with high accuracy for non-small cell lung cancer. J. Thorac. Oncol. 1(7), 622-628 (2006).
106. Dressman HK, Hans C, Bild A et al.: Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12(3), 819-826 (2006).
107. Chen H-Y, Yu S-L, Chen C-H et al.: A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356(1), 11-20 (2007).
108. Cronin M, Sangli C, Liu ML et al.: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53(6), 1084-1091 (2007).
109. Rouzier R, Rajan R, Wagner P et al.: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl Acad. Sci. USA 102(23), 8315-8320 (2005).
110. Modlich O, Prisack H-B, Pitschke G et al.: Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin. Cancer Res. 10(10), 3410-3421 (2004).
111. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24(5), 778-789 (2006).
112. Dyrskjot L, Thykjaer T, Kruhoffer M et al.: Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33(1), 90-96 (2003).
113. Dyrskjot L, Kruhoffer M, Thykjaer T et al.: Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64(11), 4040-4048 (2004).
114. Elsamman E, Fukumori T, Ewis AA et al.: Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results. Urol. Oncol. 24(2), 109-115 (2006).
115. Sanchez-Carbayo M, Socci ND, Charytonowicz E et al.: Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 62(23), 6973-6980 (2002).
116. Blaveri E, Simko JP, Korkola JE et al.: Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 11(11), 4044-4055 (2005).
117. Takata R, Katagiri T, Kanehira M et al.: Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11(7), 2625-2636 (2005).
118. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259-269 (2006).
119. Hayashita Y, Osada H, Tatematsu Y et al.: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65(21), 9628-9632 (2005).
120. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene 26(19), 2799-2803 (2007).
121. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14), 6029-6033 (2005).
122. Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25(46), 6188-6196 (2006).
123. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat. Rev. Cancer 6(11), 857-866 (2006).
124. Tavazoie SF, Alarcon C, Oskarsson T et al.: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-152 (2008).
125. Yanaihara N, Caplen N, Bowman E et al.: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006).
126. Lu J, Getz G, Miska EA et al.: MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005).
127. Iorio MV, Ferracin M, Liu CG et al.: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065-7070 (2005).
128. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 67(13), 6130-6135 (2007).
129. Volinia S, Calin GA, Liu CG et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257-2261 (2006).
130. Bloomston M, Frankel WL, Petrocca F et al.: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297(17), 1901-1908 (2007).
131. Neely LA, Rieger-Christ KM, Neto BS et al.: A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol. Oncol. (2009) (Epub ahead of print).
132. Sylvester RJ: Combining a molecular profile with a clinical and pathological profile: biostatistical considerations. Scand. J. Urol. Nephrol. Suppl. (218), 185-190 (2008).
133. Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF: Screening for bladder cancer using urine-based tumor markers. Minerva Urol. Nefrol. 60(4), 247-253 (2008).
134. Rosenblatt R, Jonmarker S, Lewensohn R et al.: Current status of prognostic immunohistochemical markers for urothelial bladder cancer. Tumour Biol. 29(5), 311-322 (2008).
135. van Tilborg AA Bangma C, Zwarthoff EC: Bladder cancer biomarkers and their role in surveillance and screening. Int. J. Urol. 16(1), 23-30 (2009).
136. Gu J, Barton Grossman H, Dinney CP, Wu X: The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics 6(6), 575-584 (2005).